Physician profile
Amber Pyles
NPI 1417735143
$1,981.95
in general payments reported to CMS, 2019-2025
12 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $78.23 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $466.51 | 2024-2025 | Caplyta |
| Abbvie INC. | $378.96 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $363.63 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $234.58 | 2025 | |
| Axsome Therapeutics, INC. | $147.37 | 2025 | Auvelity |
| Alkermes, INC. | $104.55 | 2025 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $77.11 | 2025 | Cobenfy |
| Corium, LLC | $57.97 | 2025 | Azstarys |
| Almatica Pharma LLC | $48.66 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $43.17 | 2025 | Jornay Pm |
| Lundbeck LLC | $41.01 | 2025 | Rexulti |
| Bausch Health US, LLC | $18.43 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Pyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.